Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

BARDA partners with GlaxoSmithKline to develop new class of antibiotic against bioterrorism threats and Gram-negative infections

Date: September 6, 2011

Company: GlaxoSmithKline of Philadelphia

Contract amount: The contact is for $38.5 million in the first two years and can be extended for a total of four years, up to a total of $94 million. Under the contract, BARDA will provide technical and financial support for the development of GSK2251052, sharing the cost and drug development risk.

About the contract:  This contract supports advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as certain life-threatening infections, known as Gram-negative infections, associated with prolonged hospitalization – the first such drug in 30 years. The contract support studies to evaluate the efficacy of GSK2251052 against bioterrorism threats, Phase II clinical trials using the drug to treat ventilator-associated pneumonia, and Phase III clinical trials using the drug to treat complicated intra-abdominal infections. In addition, the contract will support initial laboratory testing to determine if the drug also provides protection against multi-drug resistant pathogens, including those containing the New Delhi Metallo-beta-lactamase-1 (NDM-1) resistance gene.

Additional information: The contract is the third to be funded under the resulting new Broad Spectrum Antimicrobials Program led by BARDA. BARDA is seeking additional proposals for broad-spectrum antimicrobials that could potentially treat or prevent illness due to biological threat agents.  Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at

Press Release:  BARDA partners to develop new class of antibiotic

Procurement Announcement:  Contract Award under BARDA-CBRN-BAA-10-100-SOL-00012

PHE Newsroom

Submit an Inquiry

Watch, Listen, Subscribe

Twitter  LinkedIn  Facebook  Instagram

Watch us on YouTube  Follow us on Flickr  Subcribe to our RSS  Subscribe to our email list

  • This page last reviewed: August 05, 2020